|Description||Cimzia® (certolizumab pegol) is a recombinant, humanised antibody Fab’ fragment against tumour necrosis factor alpha (TNFα) expressed in Escherichia coli and conjugated to polyethylene glycol (PEG).|
Cimzia® is indicated for the treatment of adult patients with severe active axial spondyloarthritis, comprising:
Cimzia®, in combination with MTX, is indicated for the treatment of active psoriatic arthritis in adults when the response to previous DMARD therapy has been inadequate.
Cimzia® is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy
|Strengths||Cimzia® 200 mg solution for injection in pre-filled syringe|
FDA approval for Rheumatoid Arthritis indication in May 2009, approval for Axial Spondylarthritis & Psoriatic Arthritis in October 2014 and approval for Psoriasis Indication in May 2018
EMA approval for RA indication in October 2009, approval for Axial Spondylarthritis & Psoriatic Arthritis Indication in October 2013 and approval for Psoriasis Indication in June 2018
Registered in KSA, Kuwait, UAE, Qatar, Bahrain, Oman, Lebanon & Tunisia.
Under registration in Morocco, Algeria & Egypt.